These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 18367459)

  • 21. Infections caused by carbapenem-resistant Gram-negative pathogens in hospitalized children.
    Maltezou HC; Kontopidou F; Katerelos P; Daikos G; Roilides E; Theodoridou M
    Pediatr Infect Dis J; 2013 Apr; 32(4):e151-4. PubMed ID: 23249908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
    Hiraki Y; Yoshida M; Masuda Y; Inoue D; Tsuji Y; Kamimura H; Karube Y; Takaki K; Kawano F
    Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections.
    Baran G; Erbay A; Bodur H; Ongürü P; Akinci E; Balaban N; Cevik MA
    Int J Infect Dis; 2008 Jan; 12(1):16-21. PubMed ID: 17513154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW
    Clin Infect Dis; 2004 Sep; 39(6):812-8. PubMed ID: 15472813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates.
    Kopterides P; Koletsi PK; Michalopoulos A; Falagas ME
    Int J Antimicrob Agents; 2007 Nov; 30(5):409-14. PubMed ID: 17851052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii.
    Tseng YC; Wang JT; Wu FL; Chen YC; Chie WC; Chang SC
    Diagn Microbiol Infect Dis; 2007 Oct; 59(2):181-90. PubMed ID: 17662564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High mortality associated with Acinetobacter species infection in liver transplant patients.
    Kim YJ; Yoon JH; Kim SI; Hong KW; Kim JI; Choi JY; Yoon SK; You YK; Lee MD; Moon IS; Kim DG; Kang MW
    Transplant Proc; 2011; 43(6):2397-9. PubMed ID: 21839276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
    Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC
    Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
    Zhang TQ; Dong L; Wang ZY; Li HY
    Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for candidemia-related mortality at a medical center in central Taiwan.
    Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW
    J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes.
    Robenshtok E; Paul M; Leibovici L; Fraser A; Pitlik S; Ostfeld I; Samra Z; Perez S; Lev B; Weinberger M
    J Hosp Infect; 2006 Nov; 64(3):282-7. PubMed ID: 16930770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic options for Acinetobacter baumannii infections.
    Vila J; Pachón J
    Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.
    Wisplinghoff H; Seifert H; Wenzel RP; Edmond MB
    Clin Microbiol Infect; 2006 Feb; 12(2):170-7. PubMed ID: 16441456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
    Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
    J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection.
    Jamulitrat S; Arunpan P; Phainuphong P
    J Med Assoc Thai; 2009 Mar; 92(3):413-9. PubMed ID: 19301737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world.
    Oliveira CF; Nogueira de Sá FR; Oliveira DS; Gottschald AF; Moura JD; Shibata AR; Troster EJ; Vaz FA; Carcillo JA
    Pediatr Emerg Care; 2008 Dec; 24(12):810-5. PubMed ID: 19050666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
    Lai HH; Liou BH; Chang YY; Kuo SC; Lee YT; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2016 Jun; 49(3):371-7. PubMed ID: 25081987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OXA (beta)-lactamases in Acinetobacter: the story so far.
    Brown S; Amyes S
    J Antimicrob Chemother; 2006 Jan; 57(1):1-3. PubMed ID: 16332731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia.
    Lemos EV; de la Hoz FP; Alvis N; Einarson TR; Quevedo E; Castañeda C; Leon Y; Amado C; Cañon O; Kawai K
    Clin Microbiol Infect; 2014 Feb; 20(2):174-80. PubMed ID: 23668595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.